in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Cambrex Buys Estonian Firm
12:58 PM MST | January 18, 2008 | Alex Scott
Cambrex says that its Cambrex Karlskoga (Karlskoga, Sweden) subsidiary has agreed to acquire privately owned active pharmaceutical ingredients (API) R&D company ProSyntest (Tallinn, Estonia). Financial terms were not disclosed. ProSyntest, spun out of Tallinn University of Technology (Tallinn) in 1990, employs 25 chemists. The company’s activities include process development, and expertise in chiral chemistries. The acquisition “will enable Cambrex to more effectively compete in the high-growth, early clinical-stage pharmaceutical custom...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee